These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15934864

  • 21. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 22. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
    Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R.
    J Hepatol; 2009 Dec; 51(6):1091-6. PubMed ID: 19836097
    [Abstract] [Full Text] [Related]

  • 23. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
    Guarino M, Picardi M, Vitello A, Pugliese N, Rea M, Cossiga V, Pane F, Caporaso N, Morisco F.
    Ann Hepatol; 2017 Dec; 16(2):198-206. PubMed ID: 28233742
    [Abstract] [Full Text] [Related]

  • 24. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM.
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [Abstract] [Full Text] [Related]

  • 25. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY, Chandrasekar PH, Masood A, Schiffer CA.
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [Abstract] [Full Text] [Related]

  • 26. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.
    Ozguroglu M, Bilici A, Turna H, Serdengecti S.
    Med Oncol; 2004 Mar; 21(1):67-72. PubMed ID: 15034216
    [Abstract] [Full Text] [Related]

  • 27. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC.
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [Abstract] [Full Text] [Related]

  • 28. [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
    Ono K, Iyama S, Matsunaga T, Sato T, Sato Y, Okuda T, Takada K, Kawano Y, Hayashi T, Miyanishi K, Sagawa T, Kobune M, Takimoto R, Kato J, Niitsu Y.
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1509-12. PubMed ID: 17876158
    [Abstract] [Full Text] [Related]

  • 29. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.
    Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, Mutou Y.
    Am J Hematol; 2001 Dec; 68(4):292-4. PubMed ID: 11754421
    [Abstract] [Full Text] [Related]

  • 30. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
    Tanaka E, Matsumoto A, Yoshizawa K, Maki N.
    Intervirology; 2008 Dec; 51 Suppl 1():3-6. PubMed ID: 18544941
    [Abstract] [Full Text] [Related]

  • 31. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B.
    Lijec Vjesn; 2004 Dec; 126(11-12):307-11. PubMed ID: 16082888
    [Abstract] [Full Text] [Related]

  • 32. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C, Castillo J.
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [Abstract] [Full Text] [Related]

  • 33. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
    Phipps C, Chen Y, Tan D.
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):5-11. PubMed ID: 26705677
    [Abstract] [Full Text] [Related]

  • 34. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
    Yang JD, Girotra M, Vaid A, Duarte-Rojo A.
    J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
    [Abstract] [Full Text] [Related]

  • 35. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy.
    Castelli R, Ferraris L, Pantaleo G, Lambertenghi Deliliers G, Cicardi M.
    Dig Liver Dis; 2016 Nov; 48(11):1394-1397. PubMed ID: 27590841
    [Abstract] [Full Text] [Related]

  • 36. A drug safety evaluation of rituximab and risk of hepatitis B.
    Riedell P, Carson KR.
    Expert Opin Drug Saf; 2014 Jul; 13(7):977-87. PubMed ID: 24821316
    [Abstract] [Full Text] [Related]

  • 37. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 38. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A, Boehm S, Hahn J, Holler E, Jilg W.
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [Abstract] [Full Text] [Related]

  • 39. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
    Koo YX, Tan DS, Tan BH, Quek R, Tao M, Lim ST.
    J Clin Oncol; 2009 May 20; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
    [No Abstract] [Full Text] [Related]

  • 40. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P.
    J Rheumatol; 2009 Jun 20; 36(6):1188-94. PubMed ID: 19447932
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.